Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
LifeSci Capital analyst Rami Katkhuda maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Oppenheimer analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $104.According to TipRanks data, the analyst has a success
Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Leerink Partners analyst Thomas Smith maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $65
Jefferies analyst Kelly Shi maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $66 to $65.According to TipRanks data, the analyst has a success
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100
On Sep 12, major Wall Street analysts update their ratings for $MoonLake Immunotherapeutics(MLTX.US)$, with price targets ranging from $55 to $100.Barclays analyst Leon Wang maintains with a hold
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Hidradenitis Suppurativa Treatment Prospects
MoonLake Immunotherap Price Target Maintained With a $62.00/Share by Needham
Barclays Sticks to Their Hold Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics: A Strong Buy on Promising Sonelokimab Trials and Market Potential
Cantor Fitzgerald Reiterates Overweight on MoonLake
MoonLake Immunotherapeutics to Host a Capital Markets Update on Wednesday, September 11
Sector Update: Health Care Stocks Ease
MoonLake Immunotherapeutics Downgraded on Concerns About Lack of Near-term Catalysts
Wolfe Research Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating
Wolfe Research analyst Andy Chen downgrades $MoonLake Immunotherapeutics(MLTX.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 68.8% and a total average return of 29
Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform
We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow